Citations

Clear

90 citation(s) found for "Lévy, Franck".

Blocking RAN translation without altering repeat RNAs rescues C9ORF72 -related ALS and FTD phenotypes
Jiang, Xin , Schaeffer, Laure, Patni, Divya, Russo, Tommaso , Lee, Chao-Zong, Aguilar, Corey, Marques, Christine , Jansen-West, Karen, Hruška-Plocháň, Marián , Ray-Soni, Ananya, Lim, Su Min , Held, Aaron , Yue, Mei, Otero, Paula Castellanos, Aryal, Sandeep , Beaussant, Hortense D. A. M. , Basu, Himanish , Takakuwa, Hiro , Daughrity, Lillian M. , Ramesh, Nandini , Costa, Paulo J. da, Quadros, Ana Rita A. A., Nolan, Matthew , Reyes, Charles Jourdan , Wheeler, Hayden J., Moran, Laura C. , Griesman, Grant , Wymann, Benjamin , Trombetta, Bianca A. , Lopez-De-Silanes, Emma Sofia , Canori, Michael, Silva, Yasmim Vieira Souza Da, Eriani, Gilbert , Albers, Mark W. , Arnold, Steven E. , Song, Yuyu , Jain, Ankur, Chiu, I., Zhang, Yong-Jie, Gao, Fen‐Biao , Wainger, Brian J. , Polymenidou, Magdalini , Petrucelli, Leonard, Martin, Franck , Lagier-Tourenne, Clotilde, Lagier‐Tourenne, Clotilde , Jansen-West, Karen R , Castellanos Otero, Paula, Da Costa, Paulo , A A Quadros, Ana Rita , Eriani, Gilbert , Albers, Mark W , Arnold, Steven E , Song, Yuyu , Chiu, Isaac M , Zhang, Yong-Jie , Gao, Fen-Biao , Wainger, Brian J , Polymenidou, Magdalini , Petrucelli, Leonard , Martin, Franck , Lagier-Tourenne, Clotilde , Lee, Chao-Zong , Jansen‐West, Karen , Ray-Soni, Ananya, Krishnan, Gopinath , Jain, Ankur , Petrucelli, Leonard

Mayo Clinic

Science | February 5, 2026 | Volume: 391 | Issue: 6785 | Pages: No page available

10.1126/science.adv2600 | PMID 41643021 Get It

GGGGCC (G 4 C 2 ) repeat expansion in C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Toxicity is thought to result from the accumulation of either repeat RNAs and/or dipeptide repeat proteins (DPRs) translated from repeat-containing transcripts through repeat-associated non-AUG (RAN) translation. To disentangle RNA from DPR toxicity, we mutated a CUG codon predominantly used to initiate DPR translation from all three reading frames. This mutation disrupted DPR synthesis while preserving the expression of repeat-containing RNAs. Despite the accumulation of RNA foci, behavioral deficits and pathological abnormalities, including p-TDP-43 inclusions, STING activation, motor neuron loss, neuroinflammation, and increased plasma neurofilament concentration, were alleviated in C9ORF72 mice. Base editing of the CUG codon also improved molecular phenotypes and survival in patient induced pluripotent stem cell–derived neurons, which highlights the potential of therapeutically targeting DPR production rather than repeat RNAs.
Clinical application and reporting of neurofilament quantification in neuropsychiatric disorders: an international overview
Yriarte, Jose, Zecca, Chiara, Logroscino, Giancarlo, Koertvelyessy, Peter, Tumani, Hayrettin, Olsen, Dorte Aalund , Alcolea, Daniel, Blennow, Kaj, Fortea, Juan M., Lleó, Alberto, Santos, Gustavo A A, Borelli, Wyllians Vendramini, Amar, Elodie Bouaziz, Bigot‐Corbel, Edith, Bjerke, Maria , Pérez, Mercedes Carretero, Chabrashvili, Tinatin, Chapman, Miles, Cusato, J, Fourier, Anthony , Galimberti, Daniela, Gezen‐Ak, Duygu, Florez, Silvia de las Heras, Sánchez, Juan José Hernández, Imperiale, Daniela, Kaczorowski, Flora, Khalil, Michael, Kuhle, Jens, Lewczuk, Piotr, Tsolaki, Magda, Blanc, M, Mroszko, Barbara, Rodríguez‐Álvarez, Jose, Kulczynska‐Przybik, Agnieszka, Nogueira, Léonor, Paquet, Claire, Baiardi, Simone, Parnetti, Lucilla, Garay, Raquel Perez, Quillard‐Muraine, Muriel, Borja, Enrique Rodriguez, Schraen‐Maschke, Susanna, Terracciano, Daniela , Bachhuber, Franziska , Tzartos, Socrates, Tzartos, John , Unterwalder, Nadine, Vermunt, Lisa, Zetterberg, Henrik, Teunissen, C., Lehmann, Sylvain , Delaby, Constance , Ladang, Aurélie , Zecca, Chiara, Logroscino, Giancarlo , Köertvelyessy, Pèter, Tumani, Hayrettin , Parchi, Piero , Quadrio, Isabelle , Hart, Melanie , Alcolea, Daniel , Blennow, Kaj , Fortea, Juan , Lleó, Alberto , Algeciras‐Schimnich, Alicia , Ayrignac, Xavier , Bedel, Aurélie , Borelli, Wyllians Vendramini , Bouaziz-Amar, Élodie , Baldeiras, Inês , Bigot‐Corbel, Edith , Casoli, Tiziana , Chabrashvili, Tinatin, Cusato, Jessica , Dursun, Erdinç , Galimberti, Daniela , Gezen‐Ak, Duygu , Gordon, Brian A. , Gouju, Julien , Flórez, Silvia de las Heras , Herwerth, Marina , Kasuga, Kensaku , Keshavan, Ashvini , Khalil, Michael , Kühle, Jens , Leithner, Christoph , Lewczuk, Piotr , Letournel, Franck , Tsolaki, Magda , Giuffrè, Guido Maria , Rodrı́guez-Álvarez, José , Musso, Giulia , Kulczyńska‐Przybik, Agnieszka , Paquet, Claire , Baiardi, Simone , Gaetani, Lorenzo , Parnetti, Lucilla , Poesen, Koen , Schraen‐Maschke, Susanna , Halbgebauer, Steffen , Tzartos, S J, Vermunt, Lisa , Wellington, Cheryl L. , Zetterberg, Henrik, Teunissen, Charlotte E. , Lehmann, Sylvain

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_104274 Get It

Abstract Background The quantification of Neurofilament Light chain (NfL) in blood and cerebrospinal fluid (CSF) has proven valuable for diagnosing and prognosing various neurological disorders, including Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, parkinsonism, multiple sclerosis, and ischemic damage. However, there is considerable variability in clinical and laboratory practices between centers, primarily due to different contexts of use (COU), analytical methods, and the application of cutoffs or scales. Additionally, for the same biochemical profile, the interpretation and reporting of results may vary from one center to another, raising concerns about the commutability of the tests. To date, no consensus has been reached among laboratories to define the most appropriate use of cutoffs or conclusions/comments based on NfL profiles. Method This international project involves 38 laboratories across 18 countries, all specialized in the biochemical diagnosis of neurological disorders. Using a questionnaire, we obtained descriptions from each center regarding their COU, pre‐analytical and analytical protocols (including the biological fluid and methods used to quantify NfL). Through a consensus approach, we developed a harmonized strategy for the use and reporting of NfL results across different centres according to their respective COU. Results Among the centers, 63% quantified NfL in the CSF, 87% in blood and 53% in both fluids. COU were as follow: frontotemporal dementia (71%), Alzheimer disease (71%), multiple sclerosis (61%), amyotrophic lateral sclerosis (61%), psychiatric syndrome (45%), Creutzfeldt‐Jakob disease (32%), Parkinson disease (39%), peripheral neuropathy (29%), traumatic brain injury (21%), Huntington's disease (13%), amyloid transthyretin related (11%) and cardiac arrest (8%). Most of the centers define pathological cutoffs based on publications (50%) and take age into account for this purpose (42%). Reporting is mostly transmitted through numeric results (95%). Conclusion Harmonizing cutoffs, reporting, and interpretation across various clinical contexts will facilitate the incorporation of this biomarker into routine clinical practice.
Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM
Solomon, Scott R. , Arnason, Jon , Johnston, Patrick, Glaß, Bertram , Mielke, Stephan , Mutsaers, Pim , Hernandez‐Ilizaliturri, Francisco J. , Morschhauser, Franck, Lunning, Matthew A. , Lin, Yi , Bhatnagar, Rashmi, Montheard, Sandrine, Mielke, Stephan , Kamdar, Manali , Bachanová, Veronika , Ibrahimi, Sami , Izutsu, Koji , Morschhauser, Franck , Ribrag, Vincent , Bhatnagar, Rashmi, Abramson, Jeremy S.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3710-3710

10.1182/blood-2025-3710 Get It

Abstract Introduction: Liso-cel is an autologous, CD19-directed, 4-1BB CAR T cell product. TRANSFORM (NCT03575351) is a global, randomized, open-label, phase 3 study of liso-cel versus SOC as second-line therapy in adults with R/R LBCL. In the TRANSFORM study, liso-cel showed superior, more durable efficacy versus SOC, with a potential long-term survival benefit and a favorable safety profile, highlighting the curative potential of liso-cel for second-line R/R LBCL. Upon completion of TRANSFORM, patients who received liso-cel could enroll into a separate, long-term follow-up (LTFU) study (NCT03435796). Here, we report results after approximately 4 years of follow-up in patients from TRANSFORM who consented to the LTFU study. Methods The TRANSFORM study compared liso-cel versus SOC (chemotherapy [R-DHAP, R-ICE, or R-GDP] followed by high-dose chemotherapy [HDCT] + ASCT) in adults aged ≤ 75 years with LBCL primary refractory to or relapsed within 12 months of first-line therapy and eligible for ASCT. Patients in the liso-cel arm underwent lymphodepletion followed by liso-cel (100 × 106 CAR+ T cells). Crossover to receive liso-cel was allowed for patients in the SOC arm. The LTFU study enrolled patients who received liso-cel and discontinued early or completed TRANSFORM; liso-cel was not administered during the LTFU study and subsequent therapies were administered at investigator discretion. Selected AEs considered related to liso-cel (malignancies, neurologic, hematologic, or rheumatologic/autoimmune disorders) and OS would be assessed at each visit (month 3 and then every 6 months from years 1 to 5, and then annually) for up to 15 years from liso-cel infusion until study withdrawal or death, whichever occurred first. OS for the combined study was defined as the time from randomization to death due to any cause. PFS for the combined TRANSFORM and LTFU studies incorporated data from TRANSFORM, assessed by an independent review committee, and from LTFU, assessed by investigators, and was defined as the time from randomization to disease progression or death from any cause. For LTFU only, OS and PFS were measured from LTFU consent to event or censoring. In cases where the patient was censored at last assessment date (without receiving new therapy) in TRANSFORM and enrolled in LTFU, LTFU data were used. For patients from the liso-cel arm of TRANSFORM who did not enroll in the LTFU study, the data from TRANSFORM were considered (ie, either an event or censored) at their last adequate assessment date or before starting new therapy. Results are reported descriptively. Results In total, 184 patients were randomized in TRANSFORM (92 per arm); key demographics and baseline characteristics were previously reported (Abramson, et al. Blood 2023). The LTFU study enrolled 67 patients who received liso-cel (liso-cel arm, n = 43; crossover from SOC arm, n = 24). The median follow-up (range) for the liso-cel arm was 16.9 months (1.3–29.7) in the LTFU study and 40.1 months (2.2–61.9) combining the TRANSFORM and LTFU studies. The median follow-ups for OS and PFS for the liso-cel arm in the LTFU study were 17.1 (16.1–21.9) and 16.9 months (16.0–21.8), respectively. In patients from the LTFU study in the liso-cel arm (n = 43), median PFS and OS were both not reached (NR) with 95% CIs of NR–NR. The 24-month rates (95% CI) of PFS and OS were 94.7% (87.4–100.0) and 95.1% (88.4–100.0), respectively. In the 92 patients randomized to the liso-cel arm, using combined data from the TRANSFORM and LTFU studies, median (95% CI) PFS was NR (12.6–NR); 48-month PFS rate was 52.2% (41.5–62.8). Median (95% CI) OS was NR (NR–NR); 48-month OS rate was 61.5% (51.2–71.7). Safety results from the LTFU study in the liso-cel arm showed no new signals compared with previous reports from TRANSFORM. AEs of any grade occurred in 2 patients (hypogammaglobulinemia and dyspnea; n = 1 each), with no second primary malignancies or serious infections. AEs of grade 3 or 4 occurred in 1 patient (dyspnea). No AEs led to death.Conclusions: After a median follow-up of approximately 4 years combining data from the TRANSFORM and LTFU studies, liso-cel continued to demonstrate long-term clinical benefit with high PFS and OS rates in patients with second-line R/R LBCL. The safety profile of liso-cel continued to be manageable with no new safety signals observed during LTFU. These results further support liso-cel as an effective second-line treatment with curative potential for R/R LBCL.
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results
Hoffmann, Marc, Chavez, Julio, Westin, Jason, Jørgensen, Judit, Munoz, Javier, Carpio, Cecilia, Perini, Guilherme, Bachy, Emmanuel, Campbell, Victoria, Riley, Caroline Hasselbalch, Morschhauser, Franck, Morillo, Daniel, Akyol, Alev, Moucheron, Berengere De, Pourdehnad, Michael, Sudhindra, Akshay, Carrancio, Soraya, Voetsch, Jessica, Yang, Gang, Perna, Serena, Michot, Jean-Marie, Hoffmann, Marc, Chavez, Julio, Westin, Jason, Jørgensen, Judit, Munoz, Javier, Carpio, Cecilia, Perini, Guilherme, Bachy, Emmanuel, Campbell, Victoria, Riley, Caroline Hasselbalch, Morschhauser, Franck, Morillo, Daniel, Akyol, Alev, Moucheron, Berengere De, Pourdehnad, Michael, Sudhindra, Akshay, Carrancio, Soraya, Voetsch, Jessica, Yang, Gang, Perna, Serena, Michot, Jean-Marie

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 479-479

10.1182/blood-2025-479 Get It

Abstract Introduction Approximately 40% of patients with DLBCL will experience relapse after initial treatment with standard-of-care chemo-immunotherapy. Effective treatment options are limited for patients who experience first-line treatment failure, particularly for those with R/R disease following CAR T-cell therapy or those not able to receive CAR T-cell therapy (Sehn et al, N Engl J Med. 2021). GOLCA is a potential, first-in-class, oral CELMoD agent designed for the treatment of lymphoma, with preferential distribution to lymphoid organs and enhanced activity in lymphoma cell lines. GOLCA drives the closed, active conformation of cereblon to induce rapid and deep degradation of Ikaros and Aiolos, leading to direct cell killing (agnostic of cell of origin) and immunomodulatory activity. In the two-part, multicenter, first-in-human Phase 1/2 study (CC-99282-NHL-001; NCT03930953), GOLCA was well tolerated and effective in patients with R/R DLBCL (Bachy et al, ICML 2025, #148). Here, we provide longer follow-up in patients with R/R DLBCL from Part B of the study. Methods Patients with R/R DLBCL and disease progression after ≥ 2 lines of therapy or transplant-ineligible patients after ≥ 1 line of therapy were included in the study. Patients received GOLCA monotherapy orally, once daily at different dosing schedules in Part A. In Part B, GOLCA was dosed at 0.2 or 0.4 mg (14 days on/14 days off) ± R. Total GOLCA treatment duration was up to 2 years or until progressive disease (PD)/unacceptable toxicity. Primary objectives included safety and recommended Phase 2 dose determination. Results As of April 3, 2025, a total of 77 patients with R/R DLBCL were enrolled in Part B Cohort C (GOLCA 0.2 mg + R, n = 39; GOLCA 0.4 mg + R, n = 38). Median age was 66 years (range, 20–86). Patients were heavily pre-treated; median number of prior treatments was 4 (range, 1–11), 55% of pts had prior CAR T-cell therapy, 38% had prior bispecific antibody treatment, and 44% were refractory to last treatment. Ten patients (13%) were ongoing, 4 completed 2 y of treatment, and 63 (82%) had discontinued treatment, mostly due to PD (n = 48 [62%]). The most common any-grade (G) treatment-emergent adverse events (AEs) in the 0.2- and 0.4-mg cohorts, respectively, were neutropenia (54% and 84%), an on-target side effect of GOLCA, and anemia (44% and 45%). G3/4 neutropenia was reported in 49% of patients with 0.2 mg and 79% with 0.4 mg, and febrile neutropenia (FN) in 5% and 16%, respectively. Granulocyte colony-stimulating factor was used in 81% and 88% of patients with neutropenia and 50% and 100% of patients with FN in the 0.2-mg and 0.4-mg cohorts. Dose interruptions (mainly due to infections/neutropenia) occurred in 49% and 53% of patients and discontinuations due to AEs occurred in 10% and 3% with 0.2 and 0.4 mg. One G5 pneumonia was considered related to study treatment (0.2 mg). The median follow-up was 11.8 months (range, 3.1–35.1) with 0.2 mg and 16.2 months (range, 3.8–31.4) with 0.4 mg. The overall response rate (ORR) in efficacy evaluable patients was 34% (complete response rate [CRR], 20%) with 0.2 mg (n = 35) and 58% with 0.4 mg (n = 36), including a CRR of 44% with this dose. In patients with prior T-cell–redirecting treatment, the ORR was 33% (CRR, 22%) with 0.2 mg (n = 18) and 56% (CRR, 38%) with 0.4 mg (n = 16). Seven of 35 (0.2 mg) and 14 of 36 (0.4 mg) patients experienced durable response > 12 months. The median time to response with both 0.2 and 0.4 mg was 1.8 months. In patients with durable responses (remained in response [CR or partial response] for more than two consecutive efficacy assessments) to GOLCA, circulating tumor DNA reduction from baseline continues to deepen over time. Response was similar across clones/tumor variants. Conclusions With additional follow-up, GOLCA + R continued to demonstrate a predictable and manageable safety profile, with no new safety signals observed at longer follow-up. Durable responses were shown in heavily pretreated patients with R/R DLBCL, including those with prior T-cell–redirecting therapy. GOLCA + R induced a decrease in circulating tumor DNA across tumor variants. These data support the ongoing development of GOLCA + R in patients with R/R non-Hodgkin lymphoma.
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Maurer, Matthew J. , Procházka, Vít , Flowers, Christopher R. , Villa, Diego , Bachy, Emmanuel , Cahn, Elliot, Fournier, Marguerite , Larson, Melissa C. , Dietrich, Caroline E. , Ghesquières, Hervé , Gandhi, Maher K. , Cheah, Chan Y. , Hawkes, Eliza A. , Seymour, John F. , Freeman, Ciara L. , Friedberg, Jonathan W. , Casulo, Carla , Móciková, Heidi , Fürst, Tomáš, Feugier, Pierre, Tilly, Hervé , Davies, Andrew , Martin, Peter , Cohen, Jonathon B. , Lossos, Izidore S. , Smedby, Karin E. , Prochazka, Vit , Flowers, Christopher R , Villa, Diego , Bachy, Emmanuel , Cahn, Elliot J, Fournier, Marguerite , Larson, Melissa C , Dietrich, Caroline E , Kridel, Robert , Gandhi, Maher K , Cheah, Chan Yoon , Hawkes, Eliza , Seymour, John F , Clausen, Michael Roost , Casulo, Carla , Habermann, Thomas , Wang, Yucai , Nastoupil, Loretta J , de Nully Brown, Peter , Janikova, Andrea , Tilly, Hervé , Davies, Andrew , Cartron, Guillaume , Burack, W Richard , Chihara, Dai , Martin, Peter , Cohen, Jonathon B , Lossos, Izidore S , Kahl, Brad S , Sehn, Laurie H , E Smedby, Karin , Salles, Gilles A , Trnĕný, Marek , Link, Brian K , Morschhauser, Franck , Cerhan, James R , Maurer, Matthew , El‐Galaly, Tarec Christoffer , Jakobsen, Lasse Hjort , Clausen, Michael Roost , Wahlin, Björn , Casulo, Carla , Habermann, Thomas M. , Wang, Yucai , Nastoupil, Loretta J. , Brown, Peter de Nully , Belada, David , Feugier, Pierre , Haïoun, Corinne , Burack, Richard , Chihara, Dai , Kahl, Brad S. , Sehn, Laurie H. , Salles, Gilles , Trněný, Marek , Link, Brian K. , Morschhauser, Franck , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | December 2, 2025 | Volume: 44 | Issue: 2 | Pages: 117-128

10.1200/jco-25-00892 | PMID 41329901 Get It

PURPOSE Although most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed. METHODS The FLIPI24 model was developed and internally validated to predict 24-month event rates using individual data from 4,485 patients treated with 1L immunochemotherapy from 10 observational cohorts of FL. Overall and cause-specific survival was further evaluated in FLIPI24 risk groups. External validation in the 1L immunochemotherapy setting was performed using the prospective observational Lymphoma Epidemiology of Outcomes (LEO) cohort (N = 565) and three randomized phase III trials (N = 3,192); extension to all patients with FL (any 1L therapy) was performed in the LEO cohort (N = 1,445) and its Molecular Epidemiology Resource subcohort (N = 1,074). RESULTS The FLIPI24 model uses age and four blood-based variables (hemoglobin, lactate dehydrogenase, beta-2 microglobulin, and WBC count). FLIPI24 showed consistent performance across validation and extension data sets, which was superior to existing prognostic tools. Across the four external immunochemotherapy validation data sets, patients with high-risk FLIPI24 (23%-32% of patients) had significantly higher 24-month event rates (22%-35%) and inferior 5-year overall survival (77%-83%) compared with patients with low-risk FLIPI24 (29%-31% of patients, 24-month event rates: 10%-12%; 5-year OS: 96%-97%). Results were consistent when evaluating lymphoma-related death and when extended to all patients with FL. CONCLUSION The FLIPI24 model robustly stratifies, at diagnosis, patients with FL at increased risk of lymphoma-related death versus patients with very low lymphoma-related mortality during the first decade after diagnosis. FLIPI24 can be used to enrich future clinical trial designs in newly diagnosed FL.
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study
Thompson, Carrie A. , Trněný, Marek , Morschhauser, Franck , Salles, Gilles , Reagan, P. M., Hertzberg, Mark P. , Zhang, Huilai , Thiéblemont, Catherine , Fonseca, Gustavo , Kim, W., Singh, Avrita, Yan, Mark, Hirata, Jamie , Sugidono, Matthew , Lee, Calvin , Sharman, Jeff P. , Mehta–Shah, Neha , Flowers, Christopher R. , Tilly, Hervé , Chua, Neil , Miall, Fiona , Tsai, Cheng‐Hong , Friedberg, Jonathan W. , Thompson, Carrie, Hu, Bei , Hirata, Jamie , Mehta-Shah, Neha , Flowers, Christopher R , Casasnovas, René-Olivier , Miall, Fiona , Kim, Tae Min , Tsai, Xavier Cheng-Hong , Salles, Gilles A , Morschhauser, Franck , Trnĕný, Marek , Hertzberg, Mark, Hu, Bei , Martelli, Maurizio , Mehta, Amitkumar , Singh, Avrita, Casasnovas, Olivier , Nasta, Sunita , Lee, Seung‐Tae

Mayo Clinic

Blood | September 25, 2025 | Volume: 147 | Issue: 3 | Pages: 254-265

10.1182/blood.2025028848 | PMID 40997297 Get It

Abstract Diffuse large B-cell lymphoma (DLBCL) poses a challenge in hematology given its varied symptoms, and the complex interplay between disease and treatment effects on health-related quality of life (HRQoL). The phase 3 POLARIX study demonstrated superior progression-free survival and a similar safety profile with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously untreated DLBCL. Here, we evaluate HRQoL through patient-reported outcome (PRO) instruments to fully characterize the patient experience in the POLARIX study. Changes from baseline in HRQoL, lymphoma symptoms, and gastrointestinal (GI) symptoms were assessed, as well as incidence and severity of common symptoms by PROs vs clinician-reported adverse events (AEs). Baseline characteristics of PRO-evaluable patients (N = 874) were consistent. Comparison between PROs and clinician-reported AEs revealed a notable discordance; patients generally reported a higher incidence of symptoms than clinicians, emphasizing the need for patient-centric tools to accurately capture the patient experience. Both treatments exhibited rapid and sustained improvements in HRQoL and lymphoma symptoms, with the most substantial improvements seen in global health status/QoL, lymphoma symptoms, fatigue, role, emotional, and social functioning. GI symptoms (diarrhea, constipation, nausea, and vomiting) were generally similar between treatment arms and returned to baseline levels after treatment completion. These HRQoL data underscore the complementarity of PROs, as an adjunct to clinician-reported AEs, in evaluating the efficacy and tolerability of new treatments, including Pola-R-CHP, which may represent a new benchmark for patient-reported HRQoL in previously untreated DLBCL. This trial was registered at www.clinicaltrials.gov as NCT03274492.
IRF4 Promotes Immune Evasion and Shapes the Tumor Microenvironment in Follicular Lymphoma
Dasari, Surendra , Wenzl, Kerstin , Nelson, Geoffrey M. , Guzman, Emmanuel Contreras , Wang, Zhiquan , Chartier, Loïc , Yang, Zhi-Zhang , Villasboas, José C. , Olson, Joshua , Mukherjee, Prithviraj , Tang, Xinyi , Gysbers, Brianna J. , Zakrzewski, Johannes L. , King, Rebecca L. , Huet, Sarah , Tesson, Bruno , Nowakowski, Grzegorz S. , Pasqualucci, Laura , Novak, Anne J. , Ansell, Stephen M. , Contreras Guzman, Emmanuel , Bhardwaj, Vaishali , Tang, Xinyi , Gysbers, Brianna J , Zakrzewski, Johannes L , King, Rebecca L , Huet, Sarah , Tesson, Bruno , Maurer, Matthew , Morschhauser, Franck , Nowakowski, Grzegorz S , Adelman, Karen , Singh, Harinder , Pasqualucci, Laura , Shlomchik, Mark , Novak, Anne J , Ansell, Stephen M , Mondello, Patrizia , Villasboas, Jose Caetano , Yang, Zhi-Zhang , Nelson, Geoffrey M , Bhardwaj, Vaishali , Maurer, Matthew J. , Morschhauser, Franck , Mondello, Patrizia , Wang, Zhiquan

Mayo Clinic

Blood Cancer Discovery | July 16, 2025 | Volume: 6 | Issue: 6 | Pages: 623-645

10.1158/2643-3230.bcd-24-0223 | PMID 40668133 Get It

Abstract Twenty percent of patients with follicular lymphoma relapse early with poor outcomes; however, the molecular mechanisms underlying this aggressive behavior are unknown. Using a multiomic approach, we show that patients with follicular lymphoma with elevated IRF4 expression (IRF4hi) have increased transformation risk, dysregulated immune signaling, and a suppressive tumor microenvironment. Loss- and gain-of-function experiments in IRF4hi lymphoma cells, along with chromatin profiling, demonstrate that IRF4 impairs their interaction with T cells by repressing antigen presentation and co-receptor gene modules while promoting the expression of cytokines that antagonize T-follicular helper cell and regulatory T-cell functions. Additionally, IRF4 rewires tumor metabolism and restricts glucose availability to immune cells. Silencing of IRF4 inhibits tumor cell growth and restores immune surveillance mechanisms, thus representing a promising target for therapy. Our data suggest that IRF4hi lymphoma cells co-opt a developmental mechanism used to exit the germinal center response in promoting a more aggressive cancer via engagement of multiple immune-evasive mechanisms. Significance: We show that IRF4 controls immune and metabolic signaling with functional effects on the cross-talk between B and T cells, resulting in a suppressive immune microenvironment when IRF4 is overexpressed in lymphoma. This underscores the importance of IRF4 as a pivotal therapeutic target to restore antitumor immunosurveillance for IRF4-associated lymphomas.
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
Kamdar, Manali , Solomon, Scott R. , Arnason, Jon , Johnston, Patrick B., Glaß, Bertram , Bachanová, Veronika , Ibrahimi, Sami , Mielke, Stephan , Mutsaers, Pim , Hernandez‐Ilizaliturri, Francisco J. , Lunning, Matthew A. , Chow, Victor A. , Montheard, Sandrine, Santamaria, Josu, Colicino, Silvia , Stepan, Lara , Izutsu, Koji , Morschhauser, Franck , Colicino, Silvia , Ogasawara, Ken , Abramson, Jeremy S , Bachanova, Veronika , Kamdar, Manali , Mielke, Stephan , Ibrahimi, Sami , Johnston, Patrick B. , Izutsu, Koji , Morschhauser, Franck , Liu, Fei‐Fei , Abramson, Jeremy S.

Mayo Clinic

Journal of Clinical Oncology | July 7, 2025 | Volume: 43 | Issue: 24 | Pages: 2671-2678

10.1200/jco-25-00399 | PMID 40623279 Get It

We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (N = 184) were randomly assigned 1:1 to liso-cel (100 × 10 6 chimeric antigen receptor–positive T cells) or SOC. Results are reported descriptively. With a median follow-up of 33.9 months, median (95% CI) event-free survival was 29.5 months (9.5 to not reached [NR]) for liso-cel versus 2.4 months (2.2 to 4.9) for SOC (hazard ratio [HR], 0.375; 95% CI, 0.259 to 0.542). Median progression-free survival was NR (12.6-NR) for liso-cel versus 6.2 months (4.3-8.6) for SOC (HR, 0.422; 95% CI, 0.279 to 0.639) with 36-month rates of 51% versus 26.5%. Median overall survival (OS) was NR for both arms (HR, 0.757; 95% CI, 0.481 to 1.191), with 66% of patients crossing over to receive liso-cel; 36-month OS rate was 63% for liso-cel versus 52% for SOC. OS HR (0.566 [95% CI, 0.359 to 0.895]) favored liso-cel when accounting for the treatment effect of crossover. Safety results were consistent with previous reports. At 3-year follow-up, liso-cel confirmed superior, more durable efficacy versus SOC with a favorable safety profile and no new safety signals. These data support liso-cel as an effective second-line treatment with curative potential for relapsed/refractory LBCL.
Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview
Delaby, Constance , Martinez‐Yriarte, Jose, Zecca, Chiara , Körtvelyessy, Péter , Tumani, Hayrettin , Quadrio, Isabelle , Hart, Melanie , Olsen, Dorte Aalund , Alcolea, Daniel, Blennow, Kaj , Bouaziz-Amar, Élodie , Baldeiras, Inês , Bigot‐Corbel, Edith , Bjerke, Maria , Perez, Mercedes Carretero, Chabrashvili, Tinatin, Chapman, Miles, Fourier, Anthony , Galimberti, Daniela , Gezen‐Ak, Duygu , Gouju, Julien , Flórez, Silvia de las Heras , Sanchez, Juanjo Hernandez, Herwerth, Marina , Imperiale, Daniele , Kaczorowski, Flora, Keshavan, Ashvini , Leithner, Christoph , Blanc, M, Rodríguez, Jose Enrique Martínez, Musso, Giulia , Nogueira, Léonor, Garay, Raquel Perez, Quillard‐Muraine, Muriel, Borja, Enrique Rodriguez, Schraen, Susanna, Terracciano, Daniela , Bachhuber, Franziska , Tzartos, Socrates J., Tzartos, John , Unterwalder, Nadine, Lehmann, Sylvain , Keshavan, Ashvini , Galimberti, Daniela , Herwerth, Marina , Ladang, Aurélie , Logroscino, Giancarlo , Tumani, Hayrettin , Parchi, Piero , Alcolea, Daniel , Fortea, Juan , Lleó, Alberto , Algeciras‐Schimnich, Alicia , Ayrignac, Xavier , Bedel, Aurélie , Santos, Gustavo Alves Andrade dos , Borelli, Wyllians Vendramini , Perez, Mercedes Carretero, Casoli, Tiziana , Cusato, Jessica , Dursun, Erdinç , Gordon, Brian A. , Sanchez, Juanjo Hernandez, Kasuga, Kensaku , Khalil, Michael , Kühle, Jens , Lewczuk, Piotr , Letournel, Franck , Tsolaki, Magda , Giuffrè, Guido Maria , Mroczko, Barbara , Kulczyńska‐Przybik, Agnieszka , Paquet, Claire , Baiardi, Simone , Gaetani, Lorenzo , Parnetti, Lucilla , Poesen, Koen , Halbgebauer, Steffen , Vermunt, Lisa , Wellington, Cheryl L. , Zetterberg, Henrik , Teunissen, Charlotte E.

Mayo Clinic

Alzheimer's & Dementia | June 23, 2025 | Volume: 21 | Issue: 6 | Pages: No page available

10.1002/alz.70343 | PMID 40551293 Get It

Abstract INTRODUCTION Neurofilament light chain (NfL) quantification aids in diagnosing and predicting neurological disorders, but clinical and laboratory practices vary across centers. Differences in result interpretation and reporting further challenge test commutability. This study aimed to review the global analytical and post‐analytical methods used for NfL measurement in routine clinical practice across different contexts. METHODS We established an international working group (WG) and distributed a survey to its members to gather information on context of use (COU), (pre) analytical methods, cutoff usage, as well as the interpretation and reporting of NfL measurements. RESULTS Among the centers, 63% measured NfL in cerebrospinal fluid (CSF), 87% in blood, and 53% in both. COU was widespread, with 50% defining pathological cutoffs based on publications and 42% considering age. Reporting was primarily done through numeric results (95%). DISCUSSION Harmonizing cutoffs, reporting, and interpretation across various clinical contexts will facilitate the incorporation of this biomarker into routine clinical practice. Highlights Unique international overview of current analytical and post‐analytical methods for neurofilament light chain (NfL) measurement in routine clinical practice. Tailored sheets for each neurological application. Strategies to harmonize cutoffs, reporting, and interpretation of NfL's measurement.